Dramatic improvement in severe-critical COVID-19 patient after tocilizumab administration: a clinical experience
- PDF |
- DOI: https://doi.org/10.15562/ism.v12i1.951 |
- Published: 2021-04-30
Open Access & Peer Reviewed
Multidisciplinary Journal of Science and
Medical Research
Multidisciplinary Journal of Science and
Medical Research
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in coronavirus disease 2019 (COVID-19) involve so many inflammatory cytokines, especially Interleukin-6 (IL-6). The usage of tocilizumab as an anti-IL-6 receptor antibody had been approved as COVID-19 medication.
Case Presentation: This article reports a 51-year-old woman diagnosed with severe-critical COVID-19. The patient made significant progress after tocilizumab administration. The patient was hospitalized for 14 days before being discharged.
Conclusion: Tocilizumab administration showed a significant improvement in COVID-19 patients. However, further investigations are needed to explain this further.
References
- Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427. doi:10.1016/j.clim.2020.108427.
- World Health Organization. Weekly epidemiological update. 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update---19-january-2021.
- Adityo S, Martin R, Ceva W, et al. Coronavirus Disease 2019: Review of Current Literatures. JPDI. 2020;7(1):45-67. doi: 10.7454/jpdi.v7i1.415.
- Samudrala PK, Kumar P, Choudhary K, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. EJP. 2020;883:173375. doi:10.1016/j.ejphar.2020.173375.
- Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12(4):372. doi:10.3390/v12040372.
- Ezzikouri S, Nourlil J, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development. Hum Vaccin Immunother. 2020;16(12):2992-3000. doi:10.1080/21645515.2020.1787068.
- Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. doi:10.1183/13993003.00607-2020.
- Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020;41(12):1100-1115. doi:10.1016/j.it.2020.10.004.
- Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. doi:10.1136/bmj.m3862.
- Ebrahimi N, Aslani S, Babaie F, et al. Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. Int Immunopharmacol. 2020;89(Pt B):107082. doi:10.1016/j.intimp.2020.107082.
- Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. doi:10.1016/j.ijantimicag.2020.105954.
- Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38-42. doi:10.1016/j.cytogfr.2020.04.002.
- Wang Y, Lu X, Li Y, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. Am J Respir Crit Care Med. 2020;201(11):1430-1434. doi:10.1164/rccm.202003-0736LE.
- Esmaeilzadeh A, Elahi R. Immunobiology and immunotherapy of COVID-19: A clinically updated overview. J Cell Physiol. 2021;236(4):2519-2543. doi:10.1002/jcp.30076.
- Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020;50(5):397-400. doi:10.1016/j.medmal.2020.05.001.
How to Cite
Kurniawati, Y., Atmaja, K. S., Suryana, K., & Putra, W. W. S. (2021). Dramatic improvement in severe-critical COVID-19 patient after tocilizumab administration: a clinical experience. Intisari Sains Medis, 12(1), 338–340. https://doi.org/10.15562/ism.v12i1.951
